drugset / Trial / NCT03474289
Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to access the safety and tolerability of the study drug known as SHR-1316 in metastatic/advanced malignancies
Timeline
- Start
- 2018-03-01
- Primary completion
- 2019-01-30
- Completion
- 2019-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | Intravenous |